Literature DB >> 23411398

Two-component covalent inhibitor.

Evan M Cornett1, Yulia V Gerasimova, Dmitry M Kolpashchikov.   

Abstract

Inhibitors that covalently damage proteins or nucleic acids offer great potency, but are difficult to rationally design and suffer from poor specificity. Here we outline a general concept for constructing covalent inhibitors, called the two-component covalent inhibitor (TCCI). The approach takes advantage of two ligand analogs equipped with pre-reactive groups. Binding of the analogs to the adjacent sites of a target biopolymer brings the pre-reactive groups in close proximity and causes their interaction followed by covalent damage of the target. In the present study we used light-activated pre-reactive groups to inactivate a DNA polymerase. It was found that the efficiency of a traditional single-component inhibitor was greatly reduced in the presence of a non-target protein, while the TCCI was not significantly affected. Our findings suggest that TCCI approach has advantages in inactivation of biopolymers in complex multi-component systems.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23411398      PMCID: PMC3602336          DOI: 10.1016/j.bmc.2013.01.021

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  24 in total

Review 1.  Photoaffinity labeling technique for studying DNA replication and DNA repair.

Authors:  Svetlana N Khodyreva; Olga I Lavrik
Journal:  Curr Med Chem       Date:  2005       Impact factor: 4.530

Review 2.  Covalent modifiers: an orthogonal approach to drug design.

Authors:  Michele H Potashman; Mark E Duggan
Journal:  J Med Chem       Date:  2009-03-12       Impact factor: 7.446

Review 3.  Photocrosslinkers illuminate interactions in living cells.

Authors:  Yoshihito Tanaka; Michelle R Bond; Jennifer J Kohler
Journal:  Mol Biosyst       Date:  2008-04-23

Review 4.  Residence time of receptor-ligand complexes and its effect on biological function.

Authors:  Peter J Tummino; Robert A Copeland
Journal:  Biochemistry       Date:  2008-04-16       Impact factor: 3.162

5.  Sensitized photomodification of mammalian DNA polymerase beta. A new approach for highly selective affinity labeling of polymerases.

Authors:  D M Kolpashchikov; N I Rechkunova; M I Dobrikov; S N Khodyreva; N A Lebedeva; O I Lavrik
Journal:  FEBS Lett       Date:  1999-04-01       Impact factor: 4.124

Review 6.  Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma.

Authors:  Trevor W Dennie; Jill M Kolesar
Journal:  Clin Ther       Date:  2009       Impact factor: 3.393

Review 7.  Bendamustine: something old, something new.

Authors:  Nishant Tageja; Jasdeepa Nagi
Journal:  Cancer Chemother Pharmacol       Date:  2010-04-08       Impact factor: 3.333

8.  Beyond picomolar affinities: quantitative aspects of noncovalent and covalent binding of drugs to proteins.

Authors:  Adam J T Smith; Xiyun Zhang; Andrew G Leach; K N Houk
Journal:  J Med Chem       Date:  2009-01-22       Impact factor: 7.446

Review 9.  Modifications to the dNTP triphosphate moiety: from mechanistic probes for DNA polymerases to antiviral and anti-cancer drug design.

Authors:  Charles E McKenna; Boris A Kashemirov; Larryn W Peterson; Myron F Goodman
Journal:  Biochim Biophys Acta       Date:  2010-01-14

Review 10.  Drugs and their molecular targets: an updated overview.

Authors:  Yves Landry; Jean-Pierre Gies
Journal:  Fundam Clin Pharmacol       Date:  2008-02       Impact factor: 2.748

View more
  1 in total

1.  Click Chemistry-Based Two-Component System for Efficient Inhibition of Human Immunodeficiency Virus (HIV) Reverse Transcriptase (RT).

Authors:  Carlos E Ledezma; Evan M Cornett; Dmitry M Kolpashchikov
Journal:  ACS Omega       Date:  2020-02-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.